Introduction
We present an interim analysis of a retrospective, multicentre observational study describing the clinical effectiveness and treatment persistence of mirikizumab at 12 weeks in routine UK clinical practice.
Aims & Methods
Data were prospectively collected at 25 UK sites from NIHR IBD BioResource participants who initiated mirikizumab treatment for ulcerative colitis (UC). Patients had a minimum of 12 weeks of follow-up, and the data were analysed retrospectively. Baseline characteristics were reported descriptively using mean (standard deviation [SD]) and number (percent [%]). For the baseline characteristics and treatment persistence analyses, only patients with baseline measurements within 12 weeks before treatment initiation were included. For the effectiveness analyses, patients were required to have follow-up measurements within 4 weeks of the 12-week endpoint and no treatment switch or colectomy before the 12-week clinic review date. Mean (standard error [SE]) change from baseline (CfB) in biomarkers of disease activity (C-reactive protein [CRP] and faecal calprotectin [FCP]) were calculated, and a Wilcoxon signed-rank test was used to compare baseline and follow-up values. Kaplan-Meier analysis was used to describe time to discontinuation.
Results
114 patients with UC were included, of whom 42.1% were female. Mean (±SD) disease duration was 10.6±8.9 years, 40.4% had extensive UC and 77.2% had an SCCAI bowel urgency score of ≥1 at baseline. Mean (±SD) baseline CRP and FCP for the overall cohort were 8.5±14.0 mg/L and 1267.1±1329.4 µg/mg, respectively. 37.7% were receiving concomitant steroids at mirikizumab initiation. 82.5% had experience with advanced therapies, 36.0% had ≥3 prior advanced therapies, and 26.3% were ustekinumab-experienced. Among those with available data, 103, 64 and 73 patients had data on persistence, bowel urgency and symptomatic remission at week 12, respectively. Treatment persistence was 91.3% (95% CI: 85.62, 97.27), 42.2% showed improvement in bowel urgency, and 46.6% were in symptomatic remission. A significant reduction in CRP was observed (mean CfB: -5.4 mg/L; SE: 2.5; p=0.042) as well as a numerical reduction in FCP (mean CfB: -642.0 µg/mg; SE: 325.5; p=0.052).
Table 1: Persistence & Effectiveness Outcomes at Week 12
| Variable | Value |
|---|
| Treatment persistence, 95% CI | [N=103] 91.3% (85.62, 97.27)
|
| Symptomatic remissiona, n (%) | [N=73] 34 (46.6)
|
| Bowel urgency improvementb, n (%) | [N=64] 27 (42.2)
|
| CfB CRP (mg/L), mean (SE) | [N=51] -5.4 (2.5; p=0.042)
|
| CfB FCP (µg/mg), mean (SE) | [N=29] -642.0 (325.5; p=0.052)
|
Abbreviations: CfB, change from baseline; CRP, c-reactive protein; FCP, faecal calprotectin.
Notes: aBowel urgency improvement is defined as a reduction in SCCAI urgency of defecation subscore of ≥1, where baseline urgency of defecation subscore was 1 or more;
bSymptomatic remission is defined as having a Mayo rectal bleeding subscore of 0 and a Mayo stool frequency subscore of either 0 or 1.
Conclusion
Data from this real-world UK cohort, of whom the majority were treatment-experienced (>80%), support the clinical effectiveness and treatment persistence of mirikizumab 12-week induction therapy in patients with moderate-to-severe UC.
Disclosure
P. Irving reports Grants from: MSD, Pfizer, Takeda, Celltrion, Galapagos; Personal Fees: AbbVie, Arena, BMS, Boomerang Medical, Celgene, Celltrion, Falk Pharma, Ferring, Galapagos, Genentech, Gilead, Hospira, Janssen, Eli Lilly and Company, MSD, Pfizer, Pharmacosmos, Prometheus, Roche, Sandoz, Samsung Bioepis, Sapphire Medical, Sandoz, Shire, Takeda, Tillotts, Topivert, VH2, Vifor Pharma, Warner Chilcott; L. von Arx, E. Dhesi, B. Gittens are employees and minor shareholders of Eli Lilly and Company; R. Piper, C. Costello, M. Mirchandani are employees of Costello Medical and consultants of Eli Lilly and Company; L. Pele received a contract from: Eli Lilly and Company; M. Parkes received Grants from: Gilead, Pfizer, AstraZeneca, Galapagos, Eli Lilly and Company, Takeda; T, Ahmad reports grants, personal fees and non-financial support from: F. Hoffmann-La Roche AG, Biogen Inc, Abbvie, Janssen, Celltrion Healthcare, Galapagos NV, Immundiagnostik, Takeda, ARENA, Gilead, Adcock Ingram Healthcare, Pfizer, Genentech, Tillotts, Johnson and Johnson, Amgen, Lilly and M.T. Sharip received Consultancy fees from: Teva and Dr Falk Pharma and Grants from: Takeda and AstraZeneca.